TAF + Emtricitabine + Elvitegravir + Cobicistat

Form: Tablet

Strength: Elvitegravir – 150 mg + Cobicistat – 150 mg + Emtricitabine – 200 mg + TAF – 10 mg

Reference Brands: Genvoya(US & EU)

Category: Anti Viral

Genvoya is a once-daily, fixed-dose combination of Tenofovir Alafenamide (TAF) 10 mg, Emtricitabine 200 mg, Elvitegravir 150 mg, and Cobicistat 150 mg, used for the treatment of HIV-1 infection. Approved by the US FDA and EMA, Genvoya offers potent viral suppression with improved renal and bone safety compared to older TDF-based regimens like Stribild. It is indicated for treatment-naïve adults and adolescents (≥12 years, ≥35 kg) with no resistance to its components. The inclusion of Cobicistat enhances Elvitegravir and TAF levels, enabling effective once-daily dosing. Genvoya simplifies HIV therapy and improves adherence through its single-tablet formulation.